Opthea Ltd
ASX:OPT
Intrinsic Value
The intrinsic value of one
OPT
stock under the Base Case scenario is
0.02
AUD.
Compared to the current market price of 0.6 AUD,
Opthea Ltd
is
Overvalued by 97%.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Opthea Ltd.
Fundamental Analysis
OPT Profitability Score
Profitability Due Diligence
Score
OPT Solvency Score
Solvency Due Diligence
Score
Opthea’s lead asset, OPT-302, is heavily reliant on successful Phase III trials in wet AMD; any negative clinical data or regulatory delays could derail the company’s primary growth driver and drain resources.
The company’s pipeline remains narrowly focused on retinal diseases, providing limited diversification; a single setback in OPT-302’s path to commercialization could disproportionately impact Opthea’s valuation and future prospects.
Ongoing development expenses and the likelihood of additional capital raises heighten the risk of shareholder dilution, especially as the firm invests substantially in late-stage clinical trials without parallel revenue streams to offset costs.
OPT-302 has shown encouraging data in earlier clinical stages and, if Phase III results confirm superior efficacy, could tap into the multi-billion-dollar wet AMD market and drive significant revenue growth.
A successful pairing of OPT-302 with existing anti-VEGF treatments may enable Opthea to position the therapy as a differentiator in a competitive market, potentially boosting both market share and adoption rates by physicians.
Opthea’s ongoing collaborations and strong intellectual property protections around VEGF-C/D inhibition could secure a durable competitive edge and improve bargaining positions in future partnerships or licensing deals.
Balance Sheet Decomposition
Opthea Ltd
Opthea Ltd
Free Cash Flow Analysis
Opthea Ltd
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Opthea Ltd
Wall St
Price Targets
OPT Price Targets Summary
Opthea Ltd
Dividends
Current shareholder yield for OPT is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
OPT
stock under the Base Case scenario is
0.02
AUD.
Compared to the current market price of 0.6 AUD,
Opthea Ltd
is
Overvalued by 97%.
